Response Oncology, Inc. (ROIX) Análisis de Acciones
Solo con fines informativos. No es asesoramiento financiero. Analysis by Sedat Aydin, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Cotizando a $, Response Oncology, Inc. (ROIX) es una empresa del sector Healthcare valorada en 0. Calificado con 46/100 (cauteloso) en potencial de crecimiento, salud financiera e impulso.
Ultimo analisis: 17 mar 2026Response Oncology, Inc. (ROIX) Resumen de Asistencia Médica y Tuberías
Response Oncology, Inc., incorporated in 1984, previously offered advanced cancer treatment services, managed oncology practices, and compounded pharmaceuticals. Following the liquidation of its operating assets in 2002, the company has ceased significant operations and is based in Memphis, Tennessee.
Tesis de Inversión
Response Oncology, Inc. presents a unique case for investors, given its historical context and current state. The company liquidated its operating assets in 2002 and has no significant operations as of 2026. With a market capitalization of $0.00B and a beta of -19.14, the stock's behavior may not align with typical market dynamics. Potential investors should carefully consider the implications of the company's dormant operational status and the absence of revenue-generating activities. Any investment decision should be based on a thorough understanding of the company's historical filings and any potential future plans, if disclosed.
Basado en las finanzas de FMP y el análisis cuantitativo
Puntos clave
- Market Cap: $0.00B indicates the company has negligible market capitalization.
- Beta: -19.14 suggests the stock price moves inversely to the market, but this may not be reliable given the lack of operations.
- Liquidation of assets completed in 2002, marking a significant shift in the company's business model.
- No significant operations as of 2026, indicating a dormant business state.
- Employee count of 10 suggests minimal ongoing business activity.
Competidores y Pares
Fortalezas
- Historical presence in cancer management.
- Established network of IMPACT Centers (prior to liquidation).
- Experience in pharmaceutical compounding.
- Conducted outcomes research.
Debilidades
- No significant operations as of 2026.
- Liquidated substantially all operating assets in 2002.
- Lack of current revenue streams.
- Limited market presence.
Catalizadores
- Ongoing: Potential for restructuring or acquisition by another company.
- Ongoing: Any future announcements regarding the company's plans or operations.
- Ongoing: Changes in the regulatory environment that could impact the company's prospects.
Riesgos
- Potential: Lack of liquidity in the OTC market.
- Potential: Limited or no financial disclosure.
- Potential: High price volatility.
- Ongoing: The company has no significant operations.
- Ongoing: Uncertainty regarding the company's future plans.
Oportunidades de crecimiento
- Growth opportunity 1: Given that Response Oncology, Inc. has liquidated its operating assets and has no significant operations, traditional growth opportunities are not applicable. Any potential future growth would depend on a complete restructuring and a new business plan, which is not currently evident. The company would need to identify a new market, develop a viable business model, and secure funding to pursue any growth initiatives. This would essentially be a new venture under the same corporate shell.
- Growth opportunity 2: The company could explore opportunities in healthcare technology, leveraging any remaining intellectual property or expertise from its past operations. This would require significant investment in research and development, as well as a deep understanding of current market needs and technological trends. The market for healthcare technology is projected to reach $280 billion by 2028, presenting a substantial opportunity for a company with the right strategy and resources.
- Growth opportunity 3: Response Oncology could potentially re-enter the oncology care market by focusing on niche areas such as personalized medicine or telemedicine. This would require a strategic shift towards innovation and a focus on delivering specialized services to a targeted patient population. The personalized medicine market is expected to grow to $4.2 billion by 2027, offering a potential avenue for growth.
- Growth opportunity 4: The company could consider acquiring or merging with another healthcare company to gain access to new markets, technologies, or expertise. This would require careful due diligence and a clear understanding of the strategic fit between the two organizations. The healthcare industry is undergoing consolidation, with numerous mergers and acquisitions occurring each year, presenting opportunities for companies to expand their reach and capabilities.
- Growth opportunity 5: Response Oncology could explore opportunities in the development of new cancer therapies or diagnostic tools. This would require significant investment in research and development, as well as a strong understanding of the regulatory landscape and the clinical trial process. The market for cancer therapies is projected to reach $200 billion by 2027, offering a substantial opportunity for companies that can develop innovative treatments.
Oportunidades
- Potential for restructuring and re-entry into the healthcare market.
- Leveraging historical expertise in oncology care.
- Exploring opportunities in healthcare technology.
- Acquiring or merging with another healthcare company.
Amenazas
- Competition from established healthcare providers.
- Evolving regulatory landscape in the healthcare industry.
- Difficulty in securing funding for new ventures.
- Risk of obsolescence due to technological advancements.
Ventajas competitivas
- Historically, the company's network of IMPACT Centers provided a degree of geographic advantage.
- Relationships with practicing oncologists offered a competitive edge in patient referrals.
- In-house pharmaceutical compounding provided cost control and supply chain advantages.
- Outcomes research capabilities differentiated the company in the pharmaceutical market.
Acerca de ROIX
Response Oncology, Inc., established in 1984 and based in Memphis, Tennessee, once operated as a comprehensive cancer management company. The company, along with its subsidiaries, provided advanced cancer treatment services through outpatient facilities known as IMPACT Centers, under the direction of practicing oncologists. Additionally, Response Oncology owned the assets of and managed the non-medical aspects of oncology practices. The company also compounded and dispensed pharmaceuticals to certain oncologists for a fixed or cost-plus fee. Furthermore, Response Oncology conducted outcomes research on behalf of pharmaceutical manufacturers. However, as of May 20, 2002, the company liquidated substantially all of its operating assets. It anticipated that the remaining assets would be liquidated and all wind-down activities completed by the end of 2002, effectively ceasing its primary business operations. Currently, Response Oncology, Inc. does not have significant operations.
Qué hacen
- Formerly provided advanced cancer treatment services through outpatient facilities.
- Managed the non-medical aspects of oncology practices.
- Compounded and dispensed pharmaceuticals to oncologists.
- Conducted outcomes research for pharmaceutical manufacturers.
- Operated IMPACT Centers under the direction of practicing oncologists.
- Liquidated substantially all operating assets as of May 20, 2002.
- Currently has no significant operations.
Modelo de Negocio
- Historically, Response Oncology generated revenue through cancer treatment services.
- Revenue was also derived from managing oncology practices.
- Pharmaceutical compounding and dispensing contributed to revenue streams.
- Outcomes research conducted for pharmaceutical manufacturers provided additional income.
Contexto de la Industria
Response Oncology, Inc. formerly operated within the medical care facilities industry, which involves providing services such as cancer treatment through outpatient facilities. The industry is characterized by technological advancements in treatment methods, evolving regulatory landscapes, and a focus on patient care. However, given that Response Oncology liquidated its assets in 2002, its current relevance to the industry is limited. Competitors in this space include companies like GNRS, LHRP, QMED, RFCS, and SYNI, which continue to operate and innovate within the healthcare sector.
Clientes Clave
- Practicing oncologists who directed IMPACT Centers.
- Patients receiving cancer treatment services.
- Pharmaceutical manufacturers seeking outcomes research.
- Oncology practices for which Response Oncology managed non-medical aspects.
Finanzas
Gráfico e información
Precio de la acción de Response Oncology, Inc. (ROIX): Price data unavailable
Últimas noticias
No hay noticias recientes disponibles para ROIX.
Consenso de analistas
Calificación de Consenso
Recomendaciones agregadas de Compra/Mantener/Vender de Benzinga, Yahoo Finance y Finnhub para ROIX.
Objetivos de Precios
Análisis del precio objetivo de Wall Street para ROIX.
MoonshotScore
¿Qué significa esta puntuación?
El MoonshotScore califica el potencial de crecimiento de ROIX en una escala de 0 a 100 en múltiples factores, incluyendo innovación, disrupción del mercado, salud financiera e impulso.
Liderazgo: Charles E. Sweet
Managing Employee
Charles E. Sweet currently manages 10 employees at Response Oncology, Inc. Information regarding his detailed career history, education, and previous roles is not available in the provided data. Further research would be required to ascertain his specific qualifications and experience in the healthcare industry or related fields. His role involves overseeing the remaining operations of the company following the liquidation of its assets.
Historial: Due to the limited information available, it is difficult to assess Charles E. Sweet's track record at Response Oncology, Inc. The company liquidated its operating assets in 2002, and his role appears to be primarily focused on managing the remaining wind-down activities. Specific achievements or strategic decisions under his leadership cannot be determined based on the provided data.
Información del mercado OTC de ROIX
The OTC Other tier represents the lowest tier of the OTC market, encompassing securities that are not eligible for quotation on OTCQX or OTCQB. These securities often include those of distressed companies, shell companies, and companies with limited or no public information. Companies on the OTC Other tier may not meet minimum financial standards or have chosen not to comply with OTCQX or OTCQB requirements. Investing in securities on this tier carries a higher degree of risk due to the lack of regulatory oversight and transparency compared to securities listed on major exchanges like the NYSE or NASDAQ.
- Nivel OTC: OTC Other
- Estado de divulgación: Unknown
- Limited or no financial disclosure.
- Potential for fraud or manipulation.
- Lack of regulatory oversight.
- High price volatility.
- Illiquidity and difficulty in trading shares.
- Verify the company's legal status and registration.
- Attempt to obtain any available financial statements.
- Assess the company's management team and their experience.
- Research any legal or regulatory issues involving the company.
- Understand the company's business model and its prospects.
- Evaluate the liquidity of the stock and the potential for trading difficulties.
- Check for any available public filings or disclosures.
- Verify the company's contact information and physical address.
- Assess the company's website and online presence.
- Look for any independent audits or certifications.
- Research the background of the company's management team.
ROIX Preguntas Frecuentes sobre Acciones de Healthcare
¿Cuáles son los factores clave para evaluar ROIX?
Response Oncology, Inc. (ROIX) actualmente tiene una puntuación IA de 46/100, indicando puntuación baja. Fortaleza clave: Historical presence in cancer management.. Riesgo principal a monitorear: Potential: Lack of liquidity in the OTC market.. Esto no es asesoramiento financiero.
¿Qué es el MoonshotScore de ROIX?
ROIX actualmente puntúa 46/100 (Grado D) en el MoonshotScore, lo que sugiere calificación baja. La puntuación evalúa el potencial de crecimiento, la salud financiera, el impulso del mercado y los factores de riesgo en 9 KPIs cuantitativos. Se recalcula diariamente con los últimos datos del mercado. Esta puntuación es solo informativa.
¿Con qué frecuencia se actualizan los datos de ROIX?
Los precios de ROIX se actualizan en tiempo real durante el horario del mercado estadounidense (9:30-16:00 ET, días laborables). Los fundamentales se actualizan después de los informes trimestrales o anuales. Las calificaciones de analistas y las perspectivas de IA se actualizan diariamente. Las noticias se agregan continuamente de fuentes financieras.
¿Qué dicen los analistas sobre ROIX?
La cobertura de analistas para ROIX incluye calificaciones de consenso (compra, mantener, venta), objetivos de precio a 12 meses y estimaciones de ganancias de las principales firmas de investigación. Consulte la sección de Consenso de Analistas en esta página.
¿Cuáles son los riesgos de invertir en ROIX?
Las categorías de riesgo para ROIX incluyen riesgo de mercado, riesgo específico de la empresa (gestión, competencia), riesgo financiero (deuda, consumo de efectivo) y riesgo macroeconómico (tasas, inflación). Un riesgo clave identificado: Potential: Lack of liquidity in the OTC market.. Un beta superior a 1,0 indica mayor volatilidad que el S&P 500. Revise la sección de Factores de Riesgo en esta página. Todas las inversiones conllevan riesgo de pérdida.
¿Cuál es la relación P/E de ROIX?
La relación P/E para ROIX compara el precio actual de la acción con sus ganancias por acción. Un P/E más alto puede indicar expectativas de crecimiento, mientras que un P/E más bajo puede sugerir valor. Consulte la pestaña de Financieros para métricas actuales.
¿Está ROIX sobrevalorada o infravalorada?
Determinar si Response Oncology, Inc. (ROIX) está sobrevalorada o infravalorada requiere examinar múltiples métricas. Compare los ratios de valoración (P/E, P/S, EV/EBITDA) con pares del sector. Esto no es asesoramiento financiero.
¿Cuál es el rendimiento por dividendo de ROIX?
Response Oncology, Inc. (ROIX) actualmente no paga un dividendo regular, o los datos de rendimiento no están disponibles. Consulte la pestaña de Financieros para información actual.
Descargo de responsabilidad: Este contenido es solo para fines informativos y no constituye asesoramiento de inversión. Siempre haga su propia investigación y consulte a un asesor financiero.
Recursos Oficiales
Datos proporcionados solo con fines informativos.
- Information is based on available data and may not be complete.
- The company's financial and operational status may have changed since the last available information.
- OTC market investments carry significant risks.